Quidel

News Release

Printer Friendly Version View printer-friendly version << Back
January 29, 2003 at 4:06 AM EST

Quidel to Present at The Wall Street Analyst Forum on February 12, 2003 at 9:00 a.m. EST

SAN DIEGO--(BUSINESS WIRE)--Jan. 29, 2003--Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, today announced that president and chief executive officer, S. Wayne Kay, will make a presentation to analysts and portfolio managers at The Wall Street Analyst Forum's Institutional Investor Conference in New York City on Wednesday, February 12, 2003, at 9:00 a.m. Eastern time. Approximately 100 public companies will be presenting at the Conference from February 10 through February 13.

Analysts and portfolio managers who wish to attend the presentation should contact The Wall Street Analyst Forum at 802/253-7596 to request additional information.

Investors may access an Internet Web cast of the presentation at:

http://events.onlinebroadcasting.com/fdfn/wsaf/021003/index.php.

The Web cast of the presentation and Q&A will be available for 30 days at the above Web address.

About Quidel

Quidel Corporation, a worldwide company helping women and their families live healthy lives, discovers, develops, manufactures and markets rapid point-of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, Strep throat, H. pylori infection, chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information that enables rapid treatment and improves health outcomes, lowers costs and increases patient satisfaction. For more information, please visit Quidel's Web site at www.quidel.com.

CONTACT:
Quidel Corporation
Paul E. Landers, 858/552-7962
or
Lippert/Heilshorn & Associates
Ina McGuinness, 310/691-7100
imcguinness@lhai.com
or
Bruce Voss, 310/691-7100
bvoss@lhai.com